Teva Patent Suit on Cipla Asthma Drug Copy Leans on FTC Targets

Teva Pharmaceutical Industries Ltd. sued Cipla Ltd. alleging its proposed copy of Qvar RediHaler infringes 12 patents for the asthma treatment—including seven the US Federal Trade Commission has targeted as “wrongfully listed” in its push for reduced drug prices.

One of the patents—US Patent No. 10,561,808, related to a dose counter for an inhaler—also is at issue in Cipla’s pending appeal of a June 2023 district court ruling that upheld the validity of it and two other patents the judge found infringed by Cipla’s generic version of Qvar, an earlier Teva product, according to a complaint filed Feb. 16 ...